Industry Impact Weighed As US Supreme Court Refuses Skinny-Label Review
Teva Vows To Fight On With ‘Additional Defenses’ As Case Returns To District Court
Teva has been denied in its attempt to convince the US Supreme Court to re-examine long-running litigation with GSK over skinny-label carve-outs of generic indications. However, the generics firm has vowed to fight on as the case is returned to the district court level, while the wider off-patent industry weighs the impact of the latest decision.
